Chelsea, MA, United States of America

Thomas Wyche

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.6

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Madison, WI (US) (2016)
  • Chelsea, MA (US) (2020 - 2021)

Company Filing History:


Years Active: 2016-2021

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Thomas Wyche

Introduction

Thomas Wyche is a notable inventor based in Chelsea, MA (US). He has made significant contributions to the field of chemistry, particularly in the development of compounds with potential therapeutic applications. With a total of 4 patents to his name, Wyche's work has garnered attention in both academic and industrial circles.

Latest Patents

Wyche's latest patents include innovative compounds and methods aimed at addressing critical health issues. One of his notable inventions is related to Forazolines, which involves an isolated compound of Formula I and its salts. This compound, characterized by its chemical formula of CHClNOS or CHBrNOS, has potential applications in treating fungal infections. Additionally, he has developed compositions and methods for modulating protease activity, which may play a role in cancer treatment.

Career Highlights

Throughout his career, Thomas Wyche has worked with esteemed organizations such as the Wisconsin Alumni Research Foundation and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Wyche has collaborated with notable colleagues, including Timothy Bugni and Douglas Braun. These partnerships have facilitated the exchange of ideas and advancements in their respective areas of expertise.

Conclusion

Thomas Wyche's innovative work and contributions to the field of chemistry highlight his role as a significant inventor. His patents reflect a commitment to addressing important health challenges through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…